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INTRODUCTION 
 
 
 
Hydroxychloroquine is a derivative of chloroquine, which belongs to a 
quinolone family. It was used as an antimalarial medication since ages, 
chloroquine was given for malaria treatment and prophylaxis, and subsequently 
they were used by rheumatologist in the treatment of rheumatoid arthritis and 
dermatologists in the treatment of lupus erythematosus. (2)(3) Expanded use of 
these drugs for non-malarial diseases resulted in the prolonged course of 
treatment and higher daily doses than that used in antimalarial therapy.  
Hydroxychloroquine (Plaquenil sulfate) ,is an antimalarial drug used in 
the treatment of various autoimmune diseases like systemic lupus 
erythematosus, rheumatoid arthritis, mixed connective tissue diseases, 
seronegative polyarthritis, juvenile chronic arthritis, discoid lupus 
erythematosus, psoriatic arthropathy, polymorphous light eruption. But it is 
used in about 80-90% in treating the patients who were diagnosed with 
rheumatoid arthritis and systemic lupus erythematosus. currently there are 
more recent advances in the treating patients  of rheumatoid arthritis and 
systemic lupus erythematosus .But hydroxychloroquine (a chloroquine 
derivative) remains the most important component of treatment of both for 
more than half a century.(3) 
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HCQ has been used as most tolerated medication comparing to others 
used for various rheumatologic and dermatological conditions. But a major 
concern of its use remains the retinal toxicity. The toxicity developing due to 
use of hydroxychloroquine is found to be rare (4), but if it occurs, vision loss 
occurring due to it  is  often irreversible, even if the medication is discontinued 
from use. It continues to progress (5)(6).It is more prone particularly when 
associated with high risk factors. It has got various side effects, but within the 
eye, it affects cornea, ciliary body and retina. (1)  
Hence the patients and the physicians prescribing the medications should 
be aware of the ocular side effects before prescribing the medication and a 
proper baseline ophthalmic evaluation is essential to rule out maculopathy. 
Therefore screening remains the major part in management. (3)The decision to 
use hydroxychloroquine should be based on risk of toxicity, reversibility and 
seriousness of the toxicity and the availability of newer techniques for 
monitoring the level of toxicity. (2)  
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REVIEW OF LITERATURE  
RHEUMATOID ARTHRITIS 
 The most common autoimmune Disease Causing arthritis is RA.  75% 
occur in women. (7) Most often begins in 4th or 5th decade of life. It occurs 
due to faulty immune system (the body’s defense system) which starts to 
produce autoantibodies against our own cell. It most commonly affects the 
small joints of the hand, such as the wrist joint, the knuckles and the middle 
joints (interphalyngeal joint of our fingers ultimately leading to deformities of 
joints in the long run of disease. Generally the chronic inflammatory 
polyarthritis affects more than 5 joints. Genes may predispose some patients in 
developing arthritis.  
 
"The Symptoms of RA are pain at the joints, swelling of the joints, early 
morning stiffness, and movement of small joints are restricted limiting their 
function often.(8) The early morning stiffness seen in active RA is most 
characteristic finding. the stiffness lasts for even 1 or 2 hours .it may be found 
in other causes of arthritis too ,but here it is typical, which may occur even in 
osteoarthritis, but don’t last for a long time. Other organs of the body such as 
the eyes, lungs are also affected. Some of the common signs and symptoms of 
RA include : 
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 continues low spikes of fever 
 anergy, lethargy 
 Loss of appetite 
 Dry mouth 
 dry eyes (other associated eye symptoms like episcleritis, scleritis, uveitis, 
  rheumatoid nodules, (may be found in some cases ,which grow beneath the 
skin in places such as the hands and elbow, which are firm in consistency) 
 Many treatment options are available now, which help the affected patients 
for suppression of their symptoms and to lead a pain free life. These 
treatment can control joint pain and swelling symptomatically, and lessen 
the joint damage further.(9) The patients who are started earlier on 
treatment have good prognosis preventing early damage  and more 
importantly don’t compromise their day to day activities.  Joint 
replacement. surgeries are avoided in these patients 
Expert management (Rheumatologist opinion) is essential   to make an 
early diagnosis of RA and to rule out diseases that may mimic RA, thus 
avoiding unwanted investigations and  treatment with multiple drugs that are 
not required. Therapy for RA has been modified since 30 years. (10)  Near, 
normal levels functioning are obtained with the current mode of treatment.. 
“Remission” is achieved within 5 years with the help of recent medications and 
the signs of active disease decrease.  
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There is no permanent cure for RA. (10)  mode of treatment varies for 
different patients depending upon the clinical condition. The treatment of RA is 
changed at least once during their lifetime. 
 Thus, patients diagnosed with RA begin treatment with disease- 
modifying antirheumatic drugs that are shortly referred as DMARDs. These 
drugs   slows the progression of the disease and also relieves the 
symptoms.  DMARDs are usually prescribed along with nonsteroidal anti-
inflammatory drugs (NSAIDs) and or low-dose corticosteroids, to relieve the 
painful symptoms. DMARDs have greatly improved the symptoms, function 
and quality of life for nearly all patients with RA. Commonly used DMARDs 
include, leflunomide ,methotrexate, hydroxychloroquine (Plaquenil) and 
sulfasalazine 
Gold is an DMARD that was prescribed in olden days as an injection 
into a muscle, but can also be given as an oral dose —auronafin 
,immunosuppresants  are also prescribed recently . 
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Recently  “biologic agents” which are biologic response modifiers are 
prescribed for very serious diseases.these are anti-TNF factors. They target  the 
immune system and prevent  the signals that lead to joint and tissue damage 
and swelling. FDA-approved drugs of this type include abatacept , adalimumab 
, anakinra , certolizumab , etanercept , golimumab , infliximab , rituximab , and 
tocilizumab (10) but the most commonly used drug in a rural setup  which is 
most commonly available is HCQ. 
HCQ (Plaquenil) is a disease-modifying anti-rheumatic drug (DMARD), 
because it can decrease the acute  symptoms of inflammation  preventing  joint 
and tissue damage and thereby  reducing  the risk of long-term disability. 
Symptoms start to improve in 2 or 3 months, full benefits are usually  achieved 
by  6 months of use. RA needs more than just the treating  medicines. Patient 
education by team of doctors including rheumatologists, primary care 
physician, ophthalmologists ,occupational and physical therapists is needed 
with frequent checkups and monitoring.  
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SYSTEMIC LUPUS ERYTHEMATOSUS 
Systemic lupus erythematosus (SLE) is  one of the most common 
autoimmune disease, which is found to be more prevalent in females.(11)  The 
production of unusual antibodies in the blood is the pathogenesis of SLE. 
Immune system of our body  normally controls any sort of infections, fighting 
against organism .similarly it recognizes our own body antigens to be foreign 
and fight against it . The cause(s) of SLE is (are) unknown, however,  factors 
such as heredity, ultraviolet light, viruses,, and drugs all may have an important  
role to play.(11) 
Lupus symptoms and signs include 
 Butterfly rash on the face 
 Appetite loss 
 Hair loss 
 Pericarditis 
 Fever 
 Raynaud's phenomenon 
 Pleuritis 
 Fatigue 
 Photosensitivity 
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Almost 10% of people with lupus isolated to the skin will develop the 
systemic form of lupus (SLE).(12) Eleven criteria help doctors to diagnose 
SLE. Treatment of SLE is directed toward decreasing inflammation and/or to 
decrease the level of autoimmune activity with anti-inflammatory medications 
for those with mild symptoms. corticosteroids and/or cytotoxic drugs 
(chemotherapy) for those with more severe lupus. 
People with SLE can prevent "flares" of disease by avoiding exposure to 
the Sun, by avoiding abrupt discontinuation of medications, (12)and constantly 
monitoring their condition with their doctor. Lupus is an autoimmune disease 
observed by acute and chronic inflammation of various tissues of the body. 
Autoimmune diseases are illnesses that occur when the body's tissues are 
attacked by its own immune system. The immune system within the body is 
complex in nature and it is designed to fight infectious agents, such as bacteria 
and other foreign microbes. One of the ways that the immune system fights 
infections is by producing antibodies for the microbes. People with lupus 
produce abnormal antibodies in their blood that target tissues within their own 
body rather than foreign infectious agents. These antibodies are referred to as 
autoantibodies. 
Because the antibodies and accompanying cells of inflammation can 
affect tissues anywhere in the body, lupus has the ability to affect a number of 
areas. Sometimes lupus can cause disease of the skin, eyes, heart, kidneys, 
lungs, joints and/or nervous system.   
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When only the skin is involved by rash, the condition is called lupus 
dermatitis or cutaneous lupus erythematosus. A form of lupus dermatitis that 
can be isolated to the skin, without internal disease, is called discoid lupus. 
When lupus involves internal organs, the condition is referred to as systemic 
lupus erythematosus (SLE).(11) 
Both discoid lupus and systemic lupus are more commonly seen in 
women than men (about eight times more common). The disease can affect all 
ages but begins from 20-45 years of age in majority of the cases. Statistics 
demonstrate that lupus is more frequent in African Americans and people of 
Asia (China and Japan). More serious organ involvement with inflammation 
occurs in the brain, liver, and kidneys. WBC can be decreased in SLE (referred 
to as leukopenia or leucopenia). Also, low blood-clotting factors called 
platelets (thrombocytopenia) can be caused by lupus. Leukopenia can increase 
the risk of infection, and thrombocytopenia can increase the risk of bleeding. 
Low RBC counts (anemia) can occur. Inflammation of muscles (myositis) can 
cause muscle pain and weakness. 
 This can lead to elevations of muscle enzyme levels in the blood. 
Blood-count abnormalities: low white blood count (WBC) or red blood count 
(RBC), or platelet count on routine complete blood count testing; leukopenia, 
anemia, an-d thrombocytopenia, respectively.   
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Detectable with standard complete blood count testing (CBC). 
Immunologic disorder (abnormal immune tests include anti-DNA or anti-Sm 
[Smith] antibodies, falsely positive blood test for syphilis, anti cardiolipin 
antibodies, lupus anticoagulant, or positive LE prep test), Antinuclear antibody 
(positive ANA antibody testing [antinuclear antibody)(13) 
There is no permanent cure for SLE. The goal of treatment is to relieve 
symptoms and protect organs by decreasing inflammation and/or the level of 
autoimmune activity in the body. The precise treatment is decided on an 
individual basis. Many people with mild symptoms may need no treatment or 
only intermittent courses of anti-inflammatory medications. Those with more 
serious illness involving damage to internal organ(s) may require high doses of 
corticosteroids in combination with other medications that suppress the body's 
immune system. 
(Plaquenil) is an antimalarial medication found to be particularly 
effective for SLE people with fatigue, skin involvement, and joint disease. 
Consistently taking Plaquenil can prevent flare-ups of lupus. Side effects are 
uncommon but include diarrhea, upset stomach, and eye-pigment changes. 
Eye-pigment changes are rare but require monitoring by an ophthalmologist 
(eye specialist) during treatment with Plaquenil. Researchers have found that 
Plaquenil significantly decreased the frequency of abnormal blood clots in 
people with systemic lupus(14).  
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Moreover, the effect seemed independent of immune suppression, 
implying that Plaquenil can directly act to prevent the blood clots. This 
fascinating study highlights an important reason for people and doctors to 
consider Plaquenil for long-term use, especially for those SLE people who are 
at some risk for blood clots in veins and arteries, such as those with 
phospholipid antibodies (cardiolipin antibodies, lupus anticoagulant, and false-
positive venereal disease research laboratory test). This means not only that 
Plaquenil reduces the chance for re-flares of SLE, but it can also be beneficial 
in thinning the blood to prevent abnormal excessive blood clotting. Plaquenil is 
commonly used in combination with other treatments for lupus. 
For resistant skin disease, other antimalarial drugs, such as chloroquine 
or quinacrine, are considered and can be used in combination with 
hydroxychloroquine. Alternative medications for skin disease include dapsone 
and retinoic acid (Retin-A).(14) 
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EPIDEMIOLOGY 
Incidence of retinopathy from chloroquine and hydroxyl chloroquine 
increases with  the duration and dose of drug taken daily. 
In US, study done by Bernstein estimated incidence of retinopathy  as 10% in 
pts  taking 250 mg/day of chloroquine and 3-4% patients taking 400 mg/day of 
hydroxychloroquine. 
incidence of retinopathy varies from 0.8% to 5%(15)(16) 
No sexual or racial predilection have been found 
No age predilection have been found, but have been associated with older 
patients as it is more prone in diseased retina.  
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HISTORY 
 In 1600-Jesuits discovered that the malaria can be  cured by bark of 
cinchona tree.(15) 
 Later at 1700-Various medical qualities of  bark  of cinchona tree was 
described.(15) 
 British and Dutch introduced  the cinchona trees to the  javan plantations 
for production of quinine at Early 1900’s. 
 In 1984-Payne detailed the benefits of quinine to treat SLE. The 4-
Aminoquinolones, chloroquine and hydroxychloroquine were found as 
effective antimalarials and does not discolour skin(16). 
 Chloroquine was first introduced by Andersag in 1934 and found it as better 
drug than quinine.(16) 
 Hydroxychloroquine was synthesized in 1946. (16) 
 And it was proposed as better alternative to chloroquine in 1955. 
 During world war-2, it was observed that servicemen with rashes and 
inflammatory arthritis who (took chloroquine for malaria prophylaxis 
experienced improvement in their autoimmune condition.(17,18,19,20) 
From then on, these drugs were frequently used to treat patients, who had 
diseases like polymorphous light eruptions, systemic lupus erythematosus, 
porphyria cutanea tarda, rheumatoid arthritis, antiphospholipid antibody 
syndrome, solar urtricaria.(21)(22)(23) 
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 1963-Hydroxychloroquine retinopathy was first explained by Braun-
Vallon. (26,27) 
 Chloroquine retinopathy was first explained by Hobbs in 1959.(25) 
 Cambiaggi first explained the classic retinal pigment changes in a patient 
receiving chloroquine for SLE. 
 1962-J.Lawson Smith introduced " the term “BULL’S EYE 
MACULOPATHY, as the classical finding of macular toxicity."(26,27) 
 The 4-aminoquinolones retinopathy occurs with the order of frequency of 
chloroquine>hydroxychloroquine>quinacrine.  
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CHEMISTRY 
Quinine is the parent molecule for antimalarials. Both 
hydroxychloroquine (C18H26CIN3O) and chloroquine (C18H26CIN3) are alkylated 
4-aminoquinolones. Chloroquine is 7 chloro-4(4-diethylamine -1-methylbutyl 
amino) quinolone and its hydroxyl derivative is 
hydroxychloroquine.(20),(30)(31) 
 
Molecular weight of HCQ is 326 and chloroquine is 320. Both 
hydroxychloroquine and chloroquine are ampiphilic weak bases based on 2 
fused aromatic rings with conjugated double bonds, the 4 aminoquinolone 
nucleus. Both HCQ AND C  cross cell membrane well.() But HCQ is 
comparitively  more polar, lesser lipophilic and has difficulty  in crossing 
across cell membrane. HCQ is more soluble than chloroquine, but both drugs  
are water soluble.(32) 
 
16 
 
Melanin and its interaction with the 4-aminoquinoles: 
The name for family of pigments is termed as melanin   and these are 
polyanionic polymers formed due to oxidation of tyrosine in melanosomes 
which are the  cellular vesicles . Melanin occur in retinal pigment epithelium of 
eye, substantia niagra of brain and in inner ear. High concentrations  are  
achieved  in the eye. The functions of melanin in the eye are to prevent scatter 
formation, absorb the  light  passing through and it will protect against free 
radicals. Melanin can be a  free radical scavengerb and can bind toxins 
Choroidal melanin is  synthesized throughout life, whereas  melanin in 
RPE is produced  for a brief interval in fetal and perinatal life with small 
production. It has been emphasized  that the  binding of 4 –AQS with melanin 
produces high local measure  of the drug which have importance in identifying 
the different  cell types that are affected particularly.  
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Animal study which shows high level of  HCQ drug uptake levels in eye 
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PHARMACOLOGY 
MOA 
MOA is not understood completely. But it may  increase pH within  the 
intracellular vacuoles, which mostly  interferes with  processing of antigens  in 
macrophages and other antigen presenting cells(APC ), thus down regulating 
the immunological response   against the peptides which are termed as the  auto 
–antigenic peptides. (28)(29)(30).Also explained by “lysosomotropism”-which 
is a property of 4AQS to accumulate in   intracellular acidic compartments and 
lysosomes  due to sequestration and protonation of drug.(33)(28) 
 lysosomal enzymatic function inhibition  is assumed to be the cause for 
both retinopathy  effects and  also the beneficial  effects of 4AQS.Toxic effects 
occur due to the lysosomes getting  exposed to 4AQS, accumulate ubiquinated 
compounds leading to , oxidative injury,apoptosis and disruption of autophagy. 
Long term use of chloroquine, induces many pathophysiological defects in the 
retina(33)(34) 
PHARMACOKINETICS 
Absorption of 4AQS after an oral dose completes within 2-4 hours. 
Metabolism is by dealkylation in liver.30-79% of oral dose is metabolized and 
,the remaining 21-70% is excreted. 3-6 months is needed  to develop full 
effects of 4AQS.(35). 
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Highest concentration is achieved in the eye. The  metabolites of urine  
has been observed in urine even after 5 years of treatment. Chloroquine traces  
was found in plasma, erythrocytes, and urine are seen 5 years or more after 
discontinuation of the drug. 
Excreted by both kidney and liver. 40-60% of unchanged form is 
excreted  or  through kidney,as metabolized. liver or kidney disease brings 
down excretion of 4AQS and leading to higher level of  drug retention and 
increased risk of retinopathy.(35)(36)(37) In case of  anuric patients,  when it 
was compared with normal renal function, the  HCQ  equilibrium level is 25-
30% more. 
SIDE EFFECTS 
In addition to its therapeutic effects, side effects may be caused by 
hydroxychloroquine. It may require immediate medical attention at the time of 
any of these side effects do occur. Side effects are usually rare while this 
medicine used for short periods of time. However, when used for  longer 
period of  time and/or when taken  in daily  high dose of intake, serious side 
effects are more likely to occur.(55)(56) 
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SEVERITY - MAJOR: 
Less Common: 
 Vision impairment/blurred vision 
 This can occur even after stopping drug or even get worser after 
stopping it. 
Rare:   Increased muscle weakness,   Sore throat and fever  ,(seizures)episodes 
 Ringing or buzzing in ears or any loss of hearing 
 Mood or other mental changes 
 Unusual tiredness 
 Unusual bleeding  
 Weakness 
Symptoms of Overdose: 
 Increased excitability 
 Headache 
 Drowsiness 
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SEVERITY – MINOR: 
Some of the side effects that can occur with hydroxychloroquine may 
not need as emergency. During treatment, the body will adopt to the medicine. 
More Common 
 Itching (common in black patients) 
 Nausea or vomiting 
 Diarrhea 
 Loss of appetite 
 Stomach cramps or pain 
 Difficulty in seeing to read  
 Headache 
Less Common 
 Nervousness or restlessness 
 Bleaching of hair or increased hair loss 
 Dizziness or lightheadedness. 
 Skin rash 
 Blue-black discoloration of skin, fingernails, or inside of mouth 
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SYSTEMIC TOXICITY 
Gastrointestinal 
Gastrointestinal side effects have included vomiting, diarrhea, nausea, 
epigastric pain and anorexia abdominal cramps. Some case of pigmentation of 
the gums has also been included.  
Nervous System 
Nervous system side effects have included nystagmus, dizziness, nerve 
deafness, vertigo, tinnitus, headache, ataxia and convulsions.  
Psychiatric 
Psychiatric side effects have included nervousness, irritability, 
nightmares, emotional changes and psychosis.  
Musculoskeletal 
Musculoskeletal side effects have included depression of tendon 
reflexes, abnormal nerve conduction, skeletal muscle palsies and skeletal 
muscle myopathy, or neuromyopathy which leads to progressive weakness and 
atrophy of proximal muscle groups and it may be associated with mild sensory 
changes. Hypoactive deep tendon reflexes and extraocular muscle palsies have 
been reported. Neuromyotoxicity has been combined with hydroxychloroquine 
concurrently with worsening renal function.  
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Dermatologic 
Dermatologic side effects have included bleaching of hair, alopecia, 
photosensitivity, nonlight-sensitive psoriasis, pruritus, skin pigmentation, 
mucosal pigmentation and skin eruptions like lichenoid, morbilliform, 
maculopapular, urticarial, Stevens-Johnson syndrome, purpuric, acute 
generalized exanthematous pustulosis, erythema annulare centrifugum and 
exfoliative dermatitis. Few case of generalized pustular drug rash has also been 
reported.  
After long-term use of hydroxychloroquine, Mucocutaneous 
hyperpigmentation over all extremities, the torso and the hairline has been 
reported in an elderly man. Skin biopsies defined sharply that red-brown fibers 
in the deep dermis and the classic "banana-shaped body" combined with 
exogenous ochronosis.  
Hematologic 
Hematologic side effects have included different blood dyscrasias such 
as leukopenia, anemia, aplastic anemia, thrombocytopenia and agranulocytosis. 
Hemolysis has been reported in individuals with glucose-6-phosphate 
dehydrogenase deficiency. 
Cardiovascular 
The relationship between hydroxychloroquine and cardiomyopathy has 
not been established. Cardiovascular side effects have rarely included 
cardiomyopathy with high regular dosages. 
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Hepatic 
Hepatic side effects have included isolated cases of fulminant hepatic 
failure and abnormal liver function.  
Metabolic 
Metabolic side effects have included exacerbation or precipitation of 
porphyria and weight loss. 
Hypersensitivity 
Hypersensitivity side effects have included hypersensitivity myocarditis 
and allergic reactions like bronchospasm, angioedema and urticaria.  
Endocrine 
Endocrine side effects have included a case report of hypoglycemia 
induced by hydroxychloroquine in a type II diabetic treated for polyarthritis.  
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DRUG INTERACTIONS 
 
 
Amiodarone Increased risk of inducing ventricular 
arrhythmias have been reported if PLAQUENIL 
is used concomitantly with other arrhythmogenic 
drugs. 
Antacids Antacids may reduce absorption of PLAQUENIL 
(as chloroquine) so that a 4 hour interval has to 
be observed between PLAQUENIL and antacid 
dosing. 
Antidiabetic drugs A decrease in doses of antidiabetic drugs may be 
required, as it may enhance the effect of 
hypoglycaemia. 
Antiepileptic drugs If coadministered , effect of antiepileptic may be 
impaired. HCQ lowers the convulsive threshold. 
Antimalarials known to 
lower the convulsion 
threshold 
Coadministration of PLAQUENIL with other 
antimalarials known to lower the convulsion 
threshold (e.g. mefloquine) may increase the risk 
of convulsions. 
Ciclosporin When ciclosporin and PLAQUENIL were co-
administered,increased plasma levels of 
ciclosporin have been found. 
Cimetidine Metabolism of HCQ is inhibited by cimetidine 
which may increase plasma concentration of the 
antimalarial. 
Digoxin May result in increased serum digoxin levels; 
serum digoxin levels should be closely monitored 
in patients receiving concomitant treatment. 
Insulin May enhance the effects of a hypoglycemic 
treatment, a decrease in doses of insulin may be 
required. 
Moxifloxacin There may be an increased risk of inducing 
ventricular arrhythmias if PLAQUENIL is used 
concomitantly with other arrhythmogenic drugs. 
Neostigmine Antagonism of effect of neostigmine is present 
when coadministered. 
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Praziquantel Chloroquine has been reported to reduce the 
bioavailability of praziquantel. Due to the 
similarities in structure and pharmacokinetic 
parameters between them. 
Pyridostigmine Antagonism of effect of pyridostigmine have 
been reported. 
Vaccine: Human diploid 
cell rabies vaccine 
Reduction of the antibody response to primary 
immunization with intradermal human diploid 
cell rabies vaccine. 
 
 
 Commonly used in rheumatological conditions, because they are very 
much effective and has fewer side effects than gold, azathioprine, 
penicillamine. 
 
 Antimalarials have different mechanism of action than other 
immunomodulating drugs making them useful in combination 
therapies.(49)(50) 
 
 They have antiatherogenic and anti-thrombotic properties.(51) 
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ANATOMY 
Macula 
The macula lutea (yellow spot) is an oval zone  located in  the posterior 
pole, lying inbetween  the   vascular arcade present temporally. It is a 
comparatively dark area ,its  diameter is 5.5mm .approximately 15 degree of 
the visual field. corresponds to macula. 
Histologically comprises of >1  ganglion cells layer, in contrast to 
presence of  single  cell layer of ganglion  in the peripheral retina. 
Xanthophyll carotenoid pigments lutein and zeaxanthein ,which are 
yellow in colour  are present in the inner layers of macula.its concentration  in 
far higher in macula than peripheral retina hence the name macula lutea-
“yellow plaque” 
Fovea centralis is the central depressed part of the macula. It’s about 
1.85mm in diameter and about 0.25 mm in thickness. It corresponds to 5 
degree of visual field and is the most sensitive part of retina. 
Foveola is 0.35 mm in diameter forms the central floor of fovea .it is 
situated about 2 disc diopter (3mm) away from the temporal edge of optic disc 
and about 1mm below the horizontal meridian. Ganglion cells are absent,  high 
density cone photoreceptors are present  in it along with  their nuclei together 
with muller cells. Umbo is a tiny depression present in the very center of 
foveolar  corresponding  to the ophthamoscopically visible  reflex in fovea  
seen in most normal eyes. 
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Loss of foveolar reflex is an early sign of damage. 
Foveolar avascular zone is located inside the fovea but outside the foveola  
Surrounding fovea are parafoveal and perifoveal areas about 0.5 mm and 1.5 
mm in diameter respectively.  
 
Retina: 
Retina, the innermost tunic of eyeball, is a  delicate,thin structure  and is 
a very transparent membrane,  extending  from optic disc till ora serrata, has a 
surface area of about 266mm2. 
The  thickness of it  at the posterior pole region  in the peripapillary 
region is about  0.56 mm, whereas  at the equator 0.18 to 0.2 mm, and at the 
level of  ora serrata approx 0.1 mm.it appears purplish red due to visual purple 
of rods. It’s a highly developed tissue of the eye. 
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MICROSCOPIC STRUCTURE OF RETINA 
Retina consists of 3 type of cells and their synapses are arranged in the 
following layers. 
1) Retinal Pigment Epithelium 
2)  Rods and cones layer 
3) External Limiting Membrane 
4) Outer Nuclear Layer 
5) Outer plexiform layer 
6) Inner nuclear layer 
7) Inner plexiform layer 
8) Ganglion cell layer 
9) Nerve fiber layer 
10) Internal limiting membrane 
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1) Retinal Pigment Epithelium 
Outermost layer of retina.it contains single layer of hexagonal shaped 
cells containing pigments. The unequal pigmentation of the cells show fine 
mottling, and it is responsible for the granular appearance of fundus. 
RPE is firmly attached to layer of bruch’s and underlying choroid and 
loosely attached to layer of rods and cones. Electron microscopy shows 
adjacent RPE cells are attached by tight junctions. (formed by zonulae  
occludens and zonulae adherens) which forms the tight outer retinal barrier. 
The RPE cells at the fovea are usually are taller, thinner and contain 
more pigment granules than rest of the areas in retina. Hence it appears darker 
than any other area. The microvilli which projects between rods and cones 
processes forms the optical part of RPE. 
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Functions of RPE 
1) Plays an important role in renewal of photoreceptors and vitamin A 
recycling 
2) The subretinal space integrity is maintained by the outer blood retinal 
barrier, which actively pumps iron and water out of this. 
3) RPE also has phagocytic function 
4) The transport of nutrients and metabolites occur through blood retinal 
barrier. 
5) The processes of photoreceptors receive their mechanical support from 
RPE. 
6) The pigment which is manufactured has the optimal function in 
absorbing light. 
2)  Layers Of Rods And Cones 
The photoreceptors (rods and cones) are the end organs of vision .they 
transform the light energy into visual impulse. Rods contain rhodopsin (a 
photosensitive substance, visual purple).this is responsible for the peripheral 
vision and for low illumination (also known as scotopic vision). 
The cones are responsible for the central vision which is highly 
discriminatory (also known as photopic vision). 
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Rods  are about 120 million and cones are about  6.5 million . 
The high density of cones are available at fovea (about 1,99,000 
cones/mm2).but ranges from 1,00,000 to 3,24,000 cones/mm2,as it is highly 
variable. The density of cones fall outside rapidly falls outside fovea which is  
only 6000 cones/mm2 which is about a distance 3mm away from fovea, and 
about 4000 cones /mm2 when the distance is about 10 mm away. The density 
of cone is higher on the nasal than the temporal retina, and slightly lower in the 
superior than the inferior retina. 
The rod free zone is present in fovea, which is 0.35 mm, corresponding 
to a visual field of 1.25 degree. The largest concentration of rods are present in 
large numbers in a ring shaped zone 5-6 mm from fovea. (about 
160,000/mm2),but it is reduced towards periphery.  
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STRUCTURE OF A PHOTORECEPTOR 
Each photoreceptor consists of a cell body and a nucleus.it lies in the 
outer nuclear layer. The cell processes extend into outer plexiform layer. The 
inner and outer segments forms layer of rods and cones. The photorceptors 
long axis is oriented to retinal surface in a perpendicular fashion. 
Rod Cell 
Rod is about 40-60 micron in length 
Outer segment of rod is cylindrical, transversely striated, refractile and 
contains numerous lipid protein lamellar discs stacked one upon the surrounded 
by cell membrane. 
Disc varies between 600-1000/rod and thickness varies from 22.5 and 
24.5mm. 
Disc contains 90% visual pigment, remaining scattered on 
plasmalemma. Inner and outer segments are attached to each other by cilium, 
and the thickness of inner segment is more than that of outer. Inner segment 
contains 2 parts ellipsoid and myoid. The inner end of rod gives rise to an outer 
rod fiber, passing through the external limiting membrane, swells into a 
densely staining nucleus (rod granule) which lies in outer nuclear layer, and 
terminates as inner rod fiber. The end of inner rod fiber contains the rod 
spherule, which is in contact with cone foot. 
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Cone cell 
Cone cell is about 40-80 micrometer long.it is largest at fovea (80 
micrometer) and shortest at periphery. 
Outer segment of cone is conical in shape, which is shorter than of rod 
and contains iodopsin. 
The lamellar discs are narrower than in rods ,which maintains continuity 
with surface plasma membrane.1000-1200 discs/cone are present ,unlike in 
rods inner segment of cones are directly continuous with its nucleus and lies in 
outer nuclear layer. Stout inner fiber runs from nucleus, whose end is provided 
with lateral processes, cone foot or cone pedicles, which lies in the outer 
plexiform layer. 
3) External Limiting Membrane 
 Fenestrated membrane extending from ora serrata to optic disc, through 
ELM, pass processes of rods and cones. 
4)  Outer Nuclear Layer 
Formed by nuclei of rods and cones. Cone nuclei are larger than rod, 
which is arranged in a single layer.  it forms the Bulk of  outer nuclear layer is 
formed by rod nuclei,which is multilayered, except in cone dominated foveal 
region. 
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5) Outer Plexiform Layer  
The synapses between cone pedicles  and rod spherules are present here. 
with the dendrites of bipolar cells and processes of horizontal cells. Its the 
junction of end organ of vision and first order neurons in retina, thickest at 
macula, and consists mostly of oblique fibers that’s deviated from fovea, also 
known as henle’s layer. 
6) Inner Nuclear Layer 
It is very thin, disappears at fovea, rests of the retina, consists of  
Bipolar cells, horizontal cells, amacrine cells, soma of muller cells, 
capillaries of central retinal vessels. 
7) Inner Plexiform Layer 
The  axons of bipolar cells (first order neurons), forms synapse with the  
dendrites of ganglion cells  (second order neuron) and the processes of 
integrative amacrine cells. This layer is absent at foveola. 
8)  Ganglion Cell Layer 
Cell bodies and nuclei of ganglion cells (second order neurons) lie 
here.it is multilayered in macula, absent in foveolar. 
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9) Nerve Fiber Layer 
Contains unmyelinated axons of ganglion cells, which pass through the 
lamina cribrosa after converging at optic nerve head.it is ensheathed by myelin 
posterior to lamina. 
10) Internal Limiting Membrane: 
It consists of true basement membrane which is PAS positive, which is 
the interface between retina and vitreous. 
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PATHOGENESIS 
BULL’S EYE MACULOPATHY 
"Bull's eye maculopathy is a characteristic appearance of 
hydroxychloroquine toxicity".(2 )(3)Area of central pigmentation of retina 
surrounded circumferentially by an area of relative hypopigmentation, 
surrounded once again by an area of increased pigmentation. This condition 
appears mostly bilaterally and symmetrically. This condition may progress to 
geographic atrophy. 
Etiology 
Mostly influenced by daily  high dose,cumulative dose when used over 
a long duration ,age more than 60 years ,presence of concommitant renal/liver 
disease,concomitant retinal disease.(39)(40) 
Risk for toxicity 
HRC  include the following, 
Daily dose more  than 400 mg (   in those  people who are  of short 
stature, a daily dosage when exceeds more than 6.5 mg/kg ideal body weight) 
or  when the total cumulative dose exceeds >1000 gram.(4)(5) 
 
 
38 
 
Obesity is an important  risk factor as the  drug do not penetrate tissues 
which are lipid rich. Since the required  dose is based on  body weight, 
improper dosing is a specific risk(47)(48)(50). 
Liver and kidney  disease  has the propensity to predispose to toxicity 
due to improper  clearance and retention of the drug. Old age (contribute to 
overall risk due to natural aging process of retinal pigment epithelium making 
it more sensitive to toxic drugs). in preexisting  retinal conditions, toxicity is 
increased  (predispose to toxicity because of the  previously damaged cellular 
events)  
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General pathology 
HCQ  maculopathy  destroys   macular rods and cones with  foveal 
cones getting spared." hence  the typical bull’s eye appearance pattern is 
described".,the pigment laden cells,which migrated into the outer nuclear layer 
is usually detected in the outer nuclear and outer plexiform layer. HCQ 
keratopathy occurs due to the deposition of hydroxychloroquine salts,which is 
unmodified and is deposited  within the epithelium.(4)(5) 
Pathophysiology 
HCQ keeps  binding  to melanin for its desired therapeutic action, 
accumulate in Retinal Pigment Epithelium, and remains there for longer 
duration  of time.greatly  toxic to RPE, which causes damage to cellular 
component causing  atrophy. basis is  due to  RPE metabolism disruption , 
which results from damage to  lysosome and  with  reduction of  phagocytic 
activity towards  outer segment of photoreceptor.  photoreceptor outer segment 
accumulation leads to degeneration of RPE , migration into the layer of  outer 
retina and consequent  loss of photoreceptor cells. 
Clinical picture 
Hydroxychloroquine  causes ocular effects , in  cornea, lens , retina 
,macula and  ciliary body. 
Acquired cone dystrophies are usually recognized by triad of signs: 
Diminished visual acquity, diminished color vision, abnormalities of photopic 
portion of electroretinogram. 
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The l toxicity in cornea ( vortex keratopathy or cornea verticillata) occurs due 
to  intraepithelial deposition of drug in a diffuse pattern , punctate or  pattern 
resembling whorl like  into the cornea, which patient experience like visual 
haloes, and which  affects vision rarely. 
Ciliary body deposition (accumulation of metabolites) decreases 
accommodative function  and is rare. 
Posterior subcapsular cataract can occur. 
Retinal side effects include macular edema.  
 "Pigmentary stippling of macula  is the earliest sign of retinal toxicity" 
and with  loss of reflex in foveolar region, which is" referred to as 
premaculopathy".  
" Annular  depigmentation zone of the retinal pigment epithelium  
develops surrounding the fovea (bulls –eye maculopathy) with perifoveal 
visual field defect present correspondingly. on  continuing treatment , the  
atrophy of retinal pigment epithelium  becomes  generalized , visual acuity loss 
occurs and loss of  peripheral visual field . Even though  the treatment is 
discontinued ,  pigment epithelial atrophy continues to progress  with certain 
time before stabilizing. 
HCQ  retinopathy 
Retinopathy is a serious pigmentary degeneration of retina which may 
lead to loss of vision. 
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Patients with lupus erythematosus are more susceptible to toxicity. HCQ 
is safer drug than chloroquine due to its lower risk of toxicity, but has a weaker 
anti-inflammatory effect than chloroquine. 
The normal daily dose of chloroquine is 250 mg. The risk of toxicity 
increases significantly when cumulative dose exceeds 300 gram, (i.e 250 mg 
daily for 3 years),or when the cumulative dose exceeds 3mg/kg/day. 
The normal daily  dose of HCQ (daily dose should  not exceed 400 
mg).The  toxicity  risk  increases  if  dose taken daily is over 6.5 mg /kg /day 
administered longer than 5 years or when the cumulative dose exceeds 1000 
gram after 5 years. 
However not all the patients receiving cumulative dose exceeding 1000 gram 
did not develop retinopathy. 
The mechanism of retinal toxicity from these drugs remains unclear. 
Both drugs affects  retinal cells  metabolism which  bind to melanin present  in 
the RPE, which may serve to concentrate or prolong their effects.(35)(36) 
Although incidence of toxicity is very low, it is of serious concern because 
associated vision loss rarely   recovers. Earliest sign of toxicity include bilateral 
paracentral visual field changes and a subtle granular depigmentation 
causing paracentral scotoma. There may be diminished colour vision. the  
symptoms are noticed mostly  only after the severe  scotomas . When 
advanced, leads to loss of the basic  visual function: visual acuity,night vision 
and peripheral vision. 
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Diagnosis 
Maculopathy is basically been divided into premaculopathy and true 
maculopathy Premaculopathy:consists of early functional and structural 
changes prior to visible fundus changes.  
Screening regularly is to detect toxicity at this stage prior to irreversible 
damage. 
High resolution OCT imaging can show loss of inner segment/outer 
segment junctional line as an early feature and is relatively insensitive. 
Fundus autoflorescence and macular pigment density assessment may 
be useful. 
 Multifocal ERG can detect early changes. 
Subtle central visual field defect may be detected, though standard 
perimetry is less sensitive than imaging modalities. 
Mild colour vision defects may be present, but ishihara charts is of low 
sensitivity. 
Early maculopathy 
Moderate reduction of vision(6/9 -6/12) and subtle macular disturbance. 
Flurosceein angiography may detect abnormality more clearly. 
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Progression of retinopathy 
Moderate to severe reduction in vision(6/36-6/60) is associated with 
corresponding detoriation of clinical appearance of macula, giving an 
appearance of bull s eye macular lesion .Retinal  arterioles are attenuated and 
pigment clumps can form in the peripheral retina. 
SCREENING RECOMMENDATIONS 
There is no established criteria for diagnosing toxicity. "The American 
academy of ophthalmology" have proposed screening procedure to detect early 
toxicity. Patient’s education is critical to ensure the importance of compliance 
with screening and its importance is understood. 
Baseline assessment before or soon after commencement of treatment is 
advisable, including documentation of functional, visual parameters together 
with ancillary testing as advisable. 
Serves as a basis for future comparison and also helps to exclude pre-
existing maculopathy, as a relative contraindication. 
The  patients in whom  HCQ  or chloroquine therapy is planned  ,they 
should have a baseline examination before starting the drug  to document any  
existing ,complicating ocular conditions, and to  record the fundus appearance 
and visual field. This examination also allows for categorization of a patient 
wether they come under high risk or low risk., and for counseling  the patients 
regarding the  risk of retinal damage. This counseling should also  be 
documented explicitly in the patients record. 
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1) Complete ophthalmologic examination including best-corrected visual 
acuity and slit lamp  examination of the cornea and dilated fundus 
examination of  retina. 
2)   Amsler grid, or Humphrey 10-2 , to recognize any unrecognized  or 
confounding preexisting problems. These tests are important because 
they may reveal a functional deficit  to be asseses at a stage when 
pigmentary changes are still not clearly found . 
 3)  Color vision testing. : It is especially important to do baseline color 
vision testing on male patients.,may also be done in later stages. 
4)  Fundus photography: fundus autoflorescence is a very significant 
investigation . This also shows if the fundus shows  pigmentary changes 
(especially macular depigmentation) that may be confused with early 
toxicity. 
5) Specialized tests like fluorescein angiography or multifocal ERG. In 
general, they are not done  routinely, but should be considered if  
underlying maculopathy is suspected , ,which should  be distinguished 
from antimalarial drug toxicity, or if the patient has  been found to have 
unusual risk factors that may predispose to early or rapid toxicity. 
Patients and their prescribing  physicians has to recognize   the 
difficulties , using present available  technology, which is cost 
effective,essentially required to  distinguish early drug toxicity from 
other types of maculopathy. 
46 
 
ANNUAL REVIEW 
In absence  of special risk factors, routine annual review with ancillary 
testing, should begin after a minimum of 5 years (43)(44)(45)(46)or if there is a 
complicating factor  like old age, age related maculopathy, hepatic/renal 
impairment. The  higher risk patients should be monitored  as the same as the  
low risk patients:   with a routine basal  complete ophthalmologic examination,  
testing with amslers grid , automated perimetry  with (Humphrey 10-2 field 
testing), all other investigations are  done optionally (objective tests) . As the   
risk status increases  with  the number of years( duration) of drug usage, 
periodical testing   with Humphrey 10-2(automated perimetry) is  preferrable to  
testing  with  Amsler grid  or to obtain fundus autoflorescence picture ,with 
optional  fundus photography may be preferred  for comparison with  baseline 
assesment done earlier.. sometimes , when eventhough visual impairment 
symptoms are not available ,fundus photography and 
Fluorescein angiography will incidentally show a bull’s eye pattern of 
depigmentation that is hard to find  clinically. Multifocal electroretinography 
tests is done to provide objective data to confirm the condition. Discontinuation 
of the drug  if needed should be discussed with patient’s rheumatologist if 
toxicity is suspected.  
The newer techniques like Fundus autoflorescence  shows paracentral 
depigmentation of RPE sparing the central fovea. 
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Spectral domain OCT technique demonstrates thinning of  outer retina 
in the parafoveal region due to destruction of outer segment.,with preservation 
of foveal region. 
Multifocal ERG demonstrates decreased signal centrally and 
paracentrally.(50)(54)  
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DIFFERENTIAL DIAGNOSIS OF BULL’S EYE  
MACULOPATHY 
 
Benign concentric annular dystrophy 
Age related macular degeneration 
Central areolar choroidal dystrophy 
Chloroquine/hydroxychloroquine retinal toxicity 
Chronic macular hole 
Cone and cone-rod dystrophies 
Stargardt disease 
 
SYSTEMIC MEDICATIONS THAT CAN CAUSE RETINAL 
TOXICITY: 
Canthaxanthine                      Deferoxamine 
Chlorpromazine                      Digoxin 
Ethambutol                              Ethylene glycol 
Isotretinoin                             Methoxyflurane 
Rifabutin                                  Sildenafil 
Tamoxifen                              Thioridazine 
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RECOMMENDATIONS FOR GOOD PRACTICE IN 
RHEUMATOLOGY AND DERMATOLOGY CLINICS  
 
• The recommended dose of  6.5mg / kg lean body weight (typically 200-
400 mg daily) should  not be exceeded  while prescribing  for every 
patient . If the patient is  found to be overweight,the body mass index 
calculator INDEX  available can be used to check  lean body weight 
.(50)(57)(58)   
• During baseline assessment ,kidney and liver function test can be   
assesed by blood investigation 
• ( Both at baseline and at annual review)  
• BCVA should be assesed with or without spectacles. 
• near vision tested , at baseline and at annual review. and  
• If the patient is able to read a small print size  as N8 or N6 at baseline 
assessment, treatment with HCQ  can be started.  
• self-administration of the Amsler test is educated and encouraged  and 
the patient may  also be  issued with the instructions to read an  Amsler 
Chart (either black on white or red on black),periodically for self 
assesment..  
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• visual symptoms or any impairment if suspected,, the patient should be 
advised to  immediately consult an ophthalmologist . If the apparent 
symptom  is  best correctable with refraction, treatment may then be 
started again... 
• Other symptoms for which referred   to an ophthalmologist   , Are 
reduced  central vision (particularly for reading), patchy central vision 
or distorted central vision whilst on  ongoing  treatment with HCQ. 
Patients should be warned to seek advice immediately from the 
prescriber  ( When there is an abrupt flare up of symptoms ,after 
withdrawal of drug.  
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AIM OF THE STUDY 
 
1) To analyze the ocular effects of Hydroxychloroquine used in the 
treatment of autoimmune diseases. 
2) To assess the duration and dosage, at which the side effects 
occur. 
3) To assess the progression and resolution of  drug induced ocular 
lesions  during follow-up. 
 
 
 
 
 
 
 
  
MATERIALS AND 
METHODS 
  
52 
 
MATERIALS AND METHODS 
 
Study Design 
 Cross-sectional prospective study was undertaken in 200 eyes of 100 
patients, who were diagnosed to have rheumatoid arthritis or systemic lupus 
erythematosus (referred from rheumatology and dermatology department),who 
were on hydroxychloroquine treatment for  a duration of more than 7 years( 
taking 400 mg tablet daily for 7 years ,whose cumulative dose becomes 1000 
gram) . 
 Study was conducted in Stanley Medical College, Chennai.  
 Study period was from 2015-2016. 
Inclusion criteria 
All age groups 
Both male and female  
Concomitant renal/liver disease 
Dose more than 6.5 mg/kg/day 
Exclusion criteria: 
Retinopathy due to other causes (DM/SHT) 
Age related macular degeneration. 
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SLE/RA patients who are on on treatment with HCQ<7 Years duration. 
1) The importance of ocular examination in them was thoroughly explained in 
patients own language 
2) Consent in patients own language was obtained from all those who were 
willing to take part in study. 
3) Any photographic records of the lesions were taken only if the patient 
consented for the same. 
4) Literature of approval attached 
 Ocular Examination Was Done With Evaluation of Supporting 
Parameters 
-Detailed history regarding the diagnosis, drug intake and its duration 
-Best corrected visual acuity (Snellans chart) 
-Slit lamp examination 
-Amslers Grid 
-Colour Vision Testing 
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-Automated Perimetry 
- Dilated Fundus Examination (0.8%Tropicamide+5%Phenylephrine) 
( slit lamp biomicroscopy 90 D And ,IDO)Fundus Autofloresence-Fundus 
Fluorescein Angiography (When Indicated) With The Proper Consent  
  
 OBSERVATION AND 
RESULTS 
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OBSERVATION 
 
Gender Distribution: N=100 
In our study, we observed 69% females and 31% males. 
TABLE-1 
Gender 
No of 
Patients 
Percentage 
(%) 
Male 31 31.0 
Female 69 69.0 
Total 100 100.0 
 
 
 
Maximum patients examined were in the female population, the higher the 
prevalence of autoimmune diseases in female population, the more prevalent is 
the hydroxychloroquine intake in females. 
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AGE WISE DISTRIBUTION 
 
TABLE 2 
 
Age 
No of 
Patients 
Positive 
Ocular 
findings 
Percentage 
<60 yrs 74 9 12% 
>60yrs 26 4 11.5% 
 
 
Maximum number of patients examined in our study  were in the age group of 
<60 years , which contributed to about 74%,but the positive ocular finding was 
more or less equal in both the group, whereas age > 60      years is considered a  
high risk factor for increased chance of retinopathy       
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Gender wise distribution of Ocular findings 
 
TABLE 3 
 
Gender 
Total no of 
Patients 
positive 
Ocular 
Findings 
Percentage 
Male 31 3 9.6% 
Female 69 10 14.49% 
Total 100 13 13% 
 
 
 
Ocular findings were more in females (14.5%), than the male population 
(9.6%), which can be attributed to the increased rate of exposure and 
comparatively lower side of weight and stature in female population who are 
prescribed the same level of dose as that of males. 
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TABLE 4 
Ocular Manifestations 
 
Ocular side Effects No of Patients 
Cornea Verticillata 1(1%) 
Posterior Sub Capsular 
Cataract 
9(9%) 
Fundus changes 
Macular Edema 1(1%) 
Bull’s Eye Maculopathy 2(2%) 
Total 13(13%) 
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TABLE 5 
Dose of drug taken according to body weight 
 
Dosage 
(mg/kg/ 
day) 
Total No 
Of 
Patients 
Cornea 
Verticil
lata 
PSC 
Macula 
Edema 
Bull’s eye 
Maculopa
thy 
% of 
BEM 
<=6.5 65 1 2  1 1.5 
>6.5 35  8 1 1 5.7 
 
 
The recommended daily dosage of the drug is 6.5mg/kg/day, but since HCQ 
tablets are prescribed as 200 mg or 400 mg, when we calculated dosage taken 
by the patient upon body weight some fell within the recommended dose 
(65%), whereas others (35%) were in the higher risk group for BEM. But 
(1.5%) risk was noted in the lower risk group too, which may be attributed to 
the longer duration of drug intake in this group. 
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TABLE 8 
Duration of treatment 
 
Duration of treatment 
Total no of 
patients 
positive 
fundus 
changes 
Other 
Ocular 
Finding 
Percentage  
>= 7yrs <10 ( 400mg 
tab * 7 yrs, cum dose > 
1000gm) 
82 2 8 2.4(%) 
>=10yrs ( 400 mg*10 
yrs, cum dose  
>1460gm) 
18 1 2 5.5(%) 
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Cumulative dose >1000 gram is an important high  risk factor in development 
of maculopathy, which is attained when the patients takes 400 mg tablet daily 
for 7 years. Not all pts taking this dose develops maculopathy, but the patients 
with lesser weight and short stature with other associated risk factors are at 
increased risk. In our study 82% of the patients were taking drug for a 
duration of 7-10 years ,and 18% above 10 years .we found the incidence of 
bull’s eye maculopathy as 2.4%(7-10yrs), whereas 5.5%(>10 years),which 
had a sharp rise in incidence. 
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TABLE 6 
Daily dosage of drug intake 
 
Dose of the 
Drug 
 
No of Patients 
positive fundus 
findings 
Percentage 
400 mg 51 2 3.9% 
200 mg 49 1 1% 
Total 100 3 3% 
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 HCQ is typically given as 200 mg/400 mg tablets irrespective of weight 
as it is commonly available .higher daily dosage is an important contributory 
factor for developing retinopathy and other side effects,which causes the rapid 
toxic accumulation of cumulative dose ,leading to more aggressive tissue 
damage.in our study we found 51% patients taking daily intake of 400mg tablet 
which caused an increased % of fundus changes(3.9%)  .Generally 200 mg is 
considered as an safer dose, but( 1%) risk was also found in patients taking 200 
mg tab as it can  be a risk factor for smaller weight individuals(<31 
kgs),especially females. 
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TABLE 7 
Presence of Kidney/Liver Disease 
 
Disease No of Patients 
positive Ocular 
finding 
Bull’s eye 
Maculopathy 
Kidney 6 3 2 
Liver 7 - - 
 
 
In our study,6% of patients had kidney disease ,of  which 3 % had ocular 
findings , of which 2 patients  were diagnosed with bull’s eye maculopathy 
.since excretion of drug is by both renal(40-60%) and hepatic route(8-25%), 
dysfunction of these leads to delay in excretion of drug, leading to 
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accumulation of drug in our body thereby increasing the cumulative dose, 
leading to increased risk of toxicity. In our study presence of kidney disease is 
found to be single most significant factor, whereas  association couldn’t be 
found  in liver disease. 
 
Treatment Status 
 
 
 
 
13% patients showed ocular manifestations out of which 2 patients were 
adviced dose reduction assesing the benefit  of drug intake over risk and the 
remaining 11 patients were adviced cessation of the treatment owing the risk of 
toxicity and the patients were followed up regularly. 
 
 
 
2 
11 
Persons with +ve Ocular finding 
Continued Discontinued
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Follow-up Table 
 
Positive Ocular 
findings 
Total 
Patients 
Follow up in months Condition 
3 6 9 Stable Worse 
Cornea 
verticillata 1 1 1 1 1 
 
PSC 9 8 6 8 7 2 
Macular edema 1 - - - - - 
BEM 2 2 1 2 2 - 
 
 
On regular followup of the patients at every 3 months who had ocular 
manifestations (irrespective of the treatment status), the corneal lesion 
remained stable. 2 of the cataract patients symptoms worsened whereas 7 
remained stable. This can be atributed to the fact the toxic effect of the drug 
continues to be there for 2-3 months  even after stoping it. The macular edema 
patient presented recently and need to be followed up. Both the BEM patients 
signs &symptoms remained stable after stopping the treatment.  
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Cornea verticillata 
 
 
 
Posterior Sub Capsular catract 
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A. Fundus Photograph of a 58 yr old female with Bull’s eye Maculopathy(on 
treatment for 12 yrs) 
          
 
B.Fundus Autofluoresence 
           
 
C.FFA showing Hyperfluoresence in parafoveal region 
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65 yr old female patient on HCQ  with macular toxicity showing autofluorescence b) AP 
showing paracentral scotoma c)ERG showing decreased center sensitivity. 
 
     
 
 
  
  
 
 
 
 
DISCUSSION 
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DISCUSSION 
 
INCIDENCE OF OCULAR TOXICITY 
 
STUDIES PERCENTAGE 
Present study 13% 
Frederick and wolfe 6.5% 
Melles-RB 7.5% 
 
The total ocular manifestations found in our study was 13% ,which included 
cornea verticillata,PSC,Fundus changes which showed increased percentage 
because of the small study sample . 
 
INCIDENCE OF BULL’S EYE MACULOPATHY 
 
STUDIES PERCENTAGE 
Present study 
7-10yrs – 2.4% 
>10yrs – 5.5% 
Melles-RB Marmor MF et al 
5-10yrs – 2% 
>10yrs – 6% 
Mavrikakis et al 
<6yrs – 0.5% 
>6yrs – 3.4% 
Wolkef Marmor MF >5yrs – 1% 
Frederick and wolfe 1.8% 
Levy et al 0.48% 
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The incidence Of HCQ toxicity varies from 0.8 to 5%  from data obtained from 
different studies.Our  study relates to that of Marmor MF Study in incidence 
percentage 
Studies Based On Age Distribution 
 
STUDY RESULTS 
Present Study Not related to age < 0.5% 
Mavrikakis et al Not related to age 0% 
Johnson and Vine <60 yrs – no case 
>60 yrs – 13 case 
Frederick and wolfe Not related to age 
 
Age of the patients is   considered an important risk factor,but no age 
preferrance was found in our study which was related to Mavrikakis but in 
Fredricks study cases were more in persons>60 yrs. 
Studies Based On Duration 
 
STUDY RESULTS 
Present Study Odds Ratio 2.68 (>10yrs) 
Melles RB Marmor MF Odds Ratio 3.22 (>10yrs) 
 
Toxicity increases when duration increases which is explained by odds ratio in 
both the present study and marmor MF. 
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Studies Based on Daily dose (400mg) 
STUDY RESULTS 
Present Study 3.9% 
Rynes et al 4% 
Manty jarvi 1.6% 
 
Cumulative factor is the major risk factor, but increased daily dose is also an 
high risk ,because it leads to rapid increase in cumulative dose leading to rapid 
tissue damage which is found to be (3.9%) in our study comparable to Rynes  
et al. 
Studies based kidney disease as a risk factor 
 
STUDY RESULTS 
Present Study Odds ratio (14.01)(95% CI) 
Marmor MF 2.08(95% CI) 
 
Relation of kidney disease forms a more significant high risk factor for 
development of retinopathy in both  above studies ,which are relatable ,as both 
falls within 95% of confidence interval.No studies related to liver disease was 
found.These data suggest that HCQ retinopathy has become more common 
than previously recognized especially at daily higher dose consumption and 
longer duration of use. 
  
 CONCLUSION 
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CONCLUSION 
 
 HCQ toxicity is becoming increasingly important these days due to 
increased popularity of the drug, screening methods available and the 
new screening recommendations. 
 The incidence of ocular manifestations was found to be 13% in our 
study. 
 The incidence of bull’s eye maculopathy was 2.4% (7-10yrs), which 
rapidly increased to 5.5% after 10yrs duration, which indicates 
cumulative dose is more important.  
 In our study ocular toxicity was found to be more prevalent in female 
population.(lower side of weight and stature compared to males) 
 Toxicity was independent of age (ocular toxicity was found to equal in 
both groups. 
 Toxicity more prevalent if dosage more than 6.5mg/kg/day (5.7%). 
 There is increased frequency if the daily dosage is more than 400mg 
(3.9%) 
 Presence of kidney disease is significant risk factor in development of 
BEM.(odds  ratio-14.01(95%CI) 
 No association with liver disease was found. 
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 Out of 13 positive patients, 2 were advised dose reduction (due to 
severity of disease)&remaining 12 were advised cessation of drug. 
 On follow up, 10 patients had stable course and 2 had worsen and 1 
needed follow up. 
  
ANNEXURES 
  
BIBLIOGRAPHY 
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PROFORMA 
Serial no: 
Name :  
Age: 
Sex: 
Occupation: 
Address : 
Ocular complaints: 
Associated  Systemic illness : 
Family history : 
Drug history 
Duration of medication 
OCULAR  EXAMINATION                                                                                                     
                                                       RE                                    LE 
Vision 
Eyelids and lashes 
Extra ocular movements 
Slit lamp examination 
Conjunctiva 
Cornea 
Anterior chamber 
Iris  
Pupil 
Lens 
Fundus examination (DO,90D,IDO) 
Colour vision:  
Fields : 
Amsler Grid: 
Automated Perimetry: 
Provisional diagonosis: 
Fluorescein Angiography: 
Date:      Reactions ( if any): 
Dye used: 
 
DIAGNOSIS: 
               
IMPRESSION: 
 
ADVICE: 
 
 
 
 
 
 
  
ABBREVATIONS 
1. HCQ – HYDROXYCHLOROQUINE 
2. C – CHLOROQUINE 
3. 4AQS – 4AMINOQUINOLONES 
4. SLE – SYSTEMIC LUPUS ERYTHEMATOSUS 
5. RA – RHEUMATOID ARTHRITIS 
6. PSC-POSTERIOR SUBCAPSULAR CATARACT 
7. BCVA – BEST CORRECTED VISUAL AQUITY 
8. BEM – BULL’S EYE MACULOPATHY 
9. APC – ANTIGEN PRESENTING CELLS 
10. RPE-RETINAL PIGMENT EPITHELIUM 
11. ILM-INTERNAL LIMITING MEMBRANE 
12. ONL-OUTER NUCLEAR LAYER 
13. OPL-OUTER PLEXIFORM LAYER 
  
  
 
MASTER CHART 
 
  
Sl.No Name Age Sex 
Disea
se 
Dur
atio
n Dosage Wt. Kidney liver 
Vn 
RT 
Vn 
LT 
Corn
ea Lens 
Fundus 
Change
s 
follow 
up 3 
months 
Follow 
up 6 
mths 
follow up 9 
months Treatment 
Dose for Body 
Wt 
1 malar 45 F RA 5 200 45 - - 6/12 6/9 - - - + - + Continued 292.5 
2 vishnu priya 55 F RA 6 200 55 - - 6/6 6/9 - - - + + - 
Discontinue
d 357.5 
3 kala 38 F SLE 5 400 45 - - 6/9 6/9 - PSC - + + + Continued 292.5 
4 lalitha 55 F RA 7 200 45 - - 6/9 6/9 - - - + + - 
Discontinue
d 292.5 
5 krishna 45 M RA 5 400 55 - - 6/12 6/12 - - - + + - Continued 357.5 
6 lakshmi 55 F SLE 6 400 60 - - 6/9 6/9 - - - + + - Continued 390 
7 mariyamal 65 F SLE 6 200 55 - - 6/6 6/6 - - - + + + Continued 357.5 
8 murugan 48 M RA 6 400 60 - - 6/9 6/6 - - - + + + Continued 390 
9 usha 63 F SLE 7 400 55 - - 6/24 6/36 - - - + - - 
Discontinue
d 357.5 
10 malar 55 F SLE 5 200 53 - - 6/9 6/9 - - - + + + Continued 344.5 
11 valamathi 45 F SLE 7 400 45 + - 6/24 6/18 + - - + - - 
Discontinue
d 292.5 
12 malliya 38 F RA 8 400 56 - - 6/9 6/9 - - - + - + 
Discontinue
d 364 
13 vimala 55 F SLE 10 200 60 - + 6/24 6/24 - - - + + + Continued 390 
14 kanaga 60 F RA 5 200 59 - - 6/12 6/2 - - - + - - 
Discontinue
d 383.5 
15 malathy 65 F SLE 7 400 63 - - 6/9 6/9 - - - + + + Continued 409.5 
16 krishnaveni 75 F SLE 8 200 62 - - 6/12 6/12 - - - + + + Continued 403 
17 manivarma 50 M RA 6 400 55 + + 6/24 6/24 - - - + + + Continued 357.5 
18 noorjahan 58 F SLE 9 400 55 + - 6/36 6/60 - PSC BEM + + + 
Discontinue
d 357.5 
19 rajasekhar 62 M RA 7 400 65 - - 6/24 6/24 - - - + + - 
Discontinue
d 422.5 
20 vignesh 37 M RA 5 400 46 - - 6/24 6/24 - - - + + - Continued 299 
21 abhinaya 39 F RA 5 200 50 - - 6/9 6/9 - - - + + - 
Discontinue
d 325 
22 priya 55 F SLE 8 400 69 - - 6/9 6/12 - - - + - - Continued 448.5 
23 kathiravan 52 M SLE 8 400 50 - - 6/9 6/9 - - - + + + 
Discontinue
d 325 
24 vinu 39 F RA 7 400 56 - - 6/6 6/6 - - - + - + Continued 364 
25 meenga 58 F RA 5 200 70 - - 6/24 6/18 - - - + - - Continued 455 
26 prathyusha 65 F RA 3 200 56 + - 6/9 6/9 - - - + + + 
Discontinue
d 364 
Sl.No Name Age Sex 
Disea
se 
Dur
atio
n Dosage Wt. Kidney liver 
Vn 
RT 
Vn 
LT 
Corn
ea Lens 
Fundus 
Change
s 
follow 
up 3 
months 
Follow 
up 6 
mths 
follow up 9 
months Treatment 
Dose for Body 
Wt 
27 vinodha 42 F RA 2 400 45 + - 6/12 6/12 - - - + + + Continued 292.5 
28 kumaran 60 M SLE 7 200 54 - - 6/12 6/12 - - - + + + Continued 351 
29 vanadhi 55 F RA 10 400 59 - - 6/18 6/18 - PSC - + + + Continued 383.5 
30 malathi 53 F RA 5 400 57 - - 6/24 6/36 - PSC - + + - Continued 370.5 
31 malar 40 F RA 7 200 63 - - 6/9 6/9 - - - + - - 
Discontinue
d 409.5 
32 
krishnamurt
hy 35 M RA 6 400 55 - - 6/9 6/9 - - - + + + 
Discontinue
d 357.5 
33 mala 55 F SLE 5 200 58 - + 6/12 6/12 - - - + - + Continued 377 
34 jayashree 65 F SLE 8 400 60 - - 6/36 6/24 - PSC - + + + 
Discontinue
d 390 
35 moorthy 55 M RA 8 200 60 - - 6/18 6/9 - - - + + + Continued 390 
36 vishnu priya 65 M RA 5 200 50 - - 6/9 6/12 - - - + + + Continued 325 
37 kathiravan 55 M RA 6 200 59 - - 6/9 6/12 - - - + + - 
Discontinue
d 383.5 
38 parthiban 49 M RA 11 400 50 - - 6/24 6/36 - PSC - + - + 
Discontinue
d 325 
39 akshaya 37 F SLE 8 400 59 - - 6/9 6/9 - - - + - + Continued 383.5 
40 mani 37 M RA 6 200 62 - - 6/12 6/9 - - - - + - Continued 403 
41 valli 55 F RA 8 400 60 - - 6/36 6/36 - 2 - - - - 
Discontinue
d 390 
42 ramesh 55 M RA 6 400 65 - + 6/12 6/9 - - - - - - Continued 422.5 
43 elangovan 39 M RA 7 400 56 - - 6/18 6/12 - - - + - - 
Discontinue
d 364 
44 saragan 50 M SLE 9 400 53 - - 6/36 6/60 - - - + + + Continued 344.5 
45 kannan 53 M RA 5 400 70 - - 6/12 6/9 - - - + - - 
Discontinue
d 455 
46 raja 65 M RA 13 200 63 - - 6/12 6/18 - PSC - - - - 
Discontinue
d 409.5 
47 subha 55 F RA 10 200 55 - - 6/36 6/36 - - - + + - Continued 357.5 
48 thiru 55 M RA 10 200 70 - - 6/60 6/36 - - - + + - Continued 455 
49 kusmal 35 F RA 6 400 69 - - 6/9 6/9 - - - + + - Continued 448.5 
50 nazriya 45 F RA 8 200 72 - - 6/24 6/24 - - - + + - Continued 468 
51 varun 55 M SLE 7 400 55 - - 6/12 6/12 - - - + + - Continued 357.5 
52 vanaja 35 F SLE 5 400 45 - - 6/6 6/6 - - - + + - Continued 292.5 
53 Gowri 50 F RA 6 200 50 - + 6/6 6/6 - - - + + + Continued 325 
Sl.No Name Age Sex 
Disea
se 
Dur
atio
n Dosage Wt. Kidney liver 
Vn 
RT 
Vn 
LT 
Corn
ea Lens 
Fundus 
Change
s 
follow 
up 3 
months 
Follow 
up 6 
mths 
follow up 9 
months Treatment 
Dose for Body 
Wt 
54 samyuktha 37 F SLE 12 400 45 - - 6/9 6/9 - - - + + - Continued 292.5 
55 jaya 55 F SLE 7 200 55 - - 6/12 6/12 - - - + - - 
Discontinue
d 357.5 
56 kala 65 F SLE 9 200 70 - - 6/18 6/18 - PSC - + - + 
Discontinue
d 455 
57 maran 65 M RA 7 200 71 - - 6/9 6/9 - - - + + - Continued 461.5 
58 priya 38 F SLE 5 400 53 - - 6/18 6/9 - - - + + + Continued 344.5 
59 manohari 59 F SLE 8 200 69 - + 6/6 6/6 - - - + + + Continued 448.5 
60 shankari 53 F SLE 7 200 58 - - 6/12 6/12 - - - + + + Continued 377 
61 murugan 37 M SLE 8 400 55 - - 6/24 6/24 - PSC - + + - Continued 357.5 
62 mala 55 F RA 10 200 60 - - 6/36 6/24 - - - + - - 
Discontinue
d 390 
63 Devi 45 F SLE 5 400 66 - - 6/12 6/12 - - - - + - Continued 429 
64 tamilselvi 65 F SLE 5 200 65 - - 6/9 6/9 - - - + + + Continued 422.5 
65 kalai 55 M RA 7 200 60 - - 6/9 6/9 - - - + + + Continued 390 
66 vidya 37 F SLE 10 200 50 + - 6/6 6/9 - - - + - - 
Discontinue
d 325 
67 bala 55 F SLE 8 200 55 - - 6/6 6/9 - - - + + - Continued 357.5 
68 pallavi 39 F RA 5 400 57 - - 6/6 6/9 - - - + + + 
Discontinue
d 370.5 
69 divya 58 F SLE 12 200 55 - - 6/12 6/18 - - - + + + Continued 357.5 
70 ilangovan 55 M SLE 14 200 60 - - 6/18 6/12 - - - + - - Continued 390 
71 banu 39 F SLE 12 200 68 - - 6/24 6/18 - - - + - + Continued 442 
72 
muthulaksh
mi 63 F SLE 5 400 55 - - 6/9 6/6 - - + + - - 
Discontinue
d 357.5 
73 kumaran 38 M RA 5 200 55 - - 6/9 6/9 - - - + - + Continued 357.5 
74 mani 55 M RA 8 200 60 - + 6/12 6/12 - - - + + - 
Discontinue
d 390 
75 shabna 49 F SLE 6 400 70 - - 6/12 6/12 - - - + + - Continued 455 
76 lakshmi 38 F RA 6 200 50 - - 6/12 6/12 - - - + + + Continued 325 
77 shemina 70 F SLE 10 400 69 - - 6/18 6/24 - - - + - + Continued 448.5 
78 eswari 63 F SLE 11 200 65 - - 6/6 6/6 - - - + + - Continued 422.5 
79 krishna 39 M RA 7 400 45 + - 6/9 6/9 - - - + - - Continued 292.5 
80 Ravi 70 M RA 10 400 66 - - 6/12 6/9 - - - + + - Continued 429 
81 Sridhar 57 M RA 6 400 74 - - 6/9 6/9 - - - - - + Continued 481 
82 Rajesh 69 M RA 8 200 77 - - 6/12 6/9 - - - + - - Continued 500.5 
Sl.No Name Age Sex 
Disea
se 
Dur
atio
n Dosage Wt. Kidney liver 
Vn 
RT 
Vn 
LT 
Corn
ea Lens 
Fundus 
Change
s 
follow 
up 3 
months 
Follow 
up 6 
mths 
follow up 9 
months Treatment 
Dose for Body 
Wt 
83 Prema 49 F SLE 5 200 55 - - 6/12 6/9 - - - + + + Continued 357.5 
84 lakshmi 55 F SLE 7 200 71 - - 6/18 6/12 - - - + - + Continued 461.5 
85 malar 43 F SLE 8 400 59 - - 6/6 6/9 - - - + - - Continued 383.5 
86 saranya 62 F SLE 9 200 75 - - 6/6 6/9 - - - - - - Continued 487.5 
87 janani 55 F SLE 6 400 57 - - 6/12 6/18 - - - - + + Continued 370.5 
88 kalaiselvi 39 F SLE 10 400 60 - - 6/24 6/18 - - - + + + Continued 390 
89 kala 60 F SLE 8 400 64 - - 6/9 6/6 - - - + - + Continued 416 
90 Vani 59 F SLE 7 200 69 - - 6/12 6/12 - - - + + - Continued 448.5 
91 Susila 62 F SLE 9 400 70 - - 6/18 6/24 - - - - - - Continued 455 
92 malini 48 F SLE 7 200 54 - - 6/6 6/6 - - - - - + Continued 351 
93 deepa 58 F SLE 8 200 62 - - 6/24 6/18 - - - + + - Continued 403 
94 kavitha 65 F SLE 8 400 55 + - 6/18 6/24 - - 
MACUL
AR 
EDEMA - - + 
Discontinue
d 357.5 
95 Malathi 55 F RA 7 400 54 - - 6/12 6/12 - - - + + + Continued 351 
96 Subha 65 F RA 10 400 70 - - 6/18 6/24 - - - + - - Continued 455 
97 valar 70 F RA 12 200 69 - - 6/60 6/60 - - BEM + + - 
Discontinue
d 448.5 
98 Vidya 56 F RA 8 200 72 - - 6/36 6/36 - - - + - - Continued 468 
99 Rajathi 35 F RA 7 400 63 - - 6/9 6/12 - - - + + + Continued 409.5 
100 Suresh 65 M RA 9 400 70 - - 6/9 6/9 - - - + + - Continued 455 
 
